The trial was divided into two different cohorts (due to safety reasons), where the patients in cohort (a) received in vitro expanded TILs and IL-2, while cohort (b) received in vitro expanded TIL, IL-2 and a unique DC vaccine program to boost in vivo the anti-tumor immune response. The gene discussed is IL2; the disease is neoplasm.